Skip to main content
Active Biotech logo

Active Biotech — Investor Relations & Filings

Ticker · ACTI ISIN · SE0023261052 LEI · 549300OJ44CLMRU8YE43 ST Professional, scientific and technical activities
Open in API
Filings indexed 828 across all filing types
Latest filing 2026-04-17 Regulatory Filings
Country SE Sweden
Listing ST ACTI

About Active Biotech

https://www.activebiotech.com/en/

Active Biotech is a biotechnology company that develops pharmaceuticals for specialist indications with high medical need, focusing on oncology and inflammatory eye disorders. The company leverages its knowledge of the immune system to advance its clinical pipeline. Its portfolio includes fully-owned projects such as tasquinimod for hematological cancers, including multiple myeloma and myelofibrosis, and laquinimod, developed as eye drops for non-infectious uveitis. Additionally, the company has licensed projects, including naptumomab, which is being developed in partnership with NeoTX for the treatment of solid tumors.

Recent filings

Filing Released Lang Actions
KALLELSE TILL ÅRSSTÄMMA
Regulatory Filings
2026-04-17 Swedish
NOTICE OF ANNUAL GENERAL MEETING
Regulatory Filings
2026-04-17 English
Annual Report (ESEF) 2025
Annual Report (ESEF) Classification · 1% confidence FY 2025
2026-04-01 Swedish
Audit Report / Information 2025
Audit Report / Information Classification · 1% confidence The document is titled 'BOKSLUTSRAPPORT 2025' (Year-end Report 2025) for Active Biotech AB. It contains a comprehensive review of the fiscal year, including financial tables (income statement, balance sheet items), a CEO statement, detailed project updates, and operational highlights. It is a full-length report (over 60,000 characters) rather than a short announcement. In the context of Swedish financial reporting, a 'Bokslutsrapport' is the equivalent of an annual or year-end financial report, which falls under the category of an Interim/Quarterly Report (IR) or Annual Report (10-K). Given it covers the full year 2025 and provides detailed financial performance, it is classified as an Annual Report. FY 2025
2026-02-12 Swedish
Audit Report / Information 2025
Audit Report / Information Classification · 1% confidence The document is titled 'YEAR END REPORT 2025' and contains comprehensive financial summaries, management commentary from the CEO, detailed project updates, and clinical trial progress. It covers the full fiscal year (Jan-Dec 2025) and includes comparative data for 2024. It is a formal, multi-page report detailing the company's performance and outlook, which fits the definition of an Interim/Quarterly Report (IR) or a year-end financial report, which is categorized under IR in this schema. FY 2025
2026-02-12 English
Number of shares and votes in Active Biotech
Share Issue/Capital Change Classification · 1% confidence The document announces a change in the total number of shares and votes in Active Biotech AB following a rights issue. This type of disclosure is a standard regulatory requirement regarding capital structure changes. It fits the 'Share Issue/Capital Change' category as it specifically details the updated share count resulting from a corporate action.
2026-01-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.